{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:05:38Z","timestamp":1774555538778,"version":"3.50.1"},"reference-count":34,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1483,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1111\/j.1365-2710.2011.01292.x","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T14:21:56Z","timestamp":1312986116000},"page":"301-307","source":"Crossref","is-referenced-by-count":25,"title":["Indirect comparison of biological treatments in refractory rheumatoid arthritis"],"prefix":"10.1155","volume":"37","author":[{"given":"M.","family":"Gallego-Galisteo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Villa-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Alegre-del Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"M\u00e1rquez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Ramos-B\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2011,8,10]]},"reference":[{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/rheumatology\/41.1.88","article-title":"The prevalence of rheumatoid arthritis in the general population of Spain","volume":"41","author":"Carmona","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB2|cit2","unstructured":"Fisterra http:\/\/www.fisterra.es"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB3|cit3","unstructured":""},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB4|cit4","unstructured":"\u00ae http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/humira\/emea-combined-h481es.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB5|cit5","unstructured":"\u00ae http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/Enbrel\/emea-combined-h262es.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB6|cit6","unstructured":"\u00ae http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/Remicade\/emea-combined-h240es.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB7|cit7","unstructured":"\u00ae http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/simponi\/emea-combined-h992es.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB8|cit8","unstructured":"\u00ae http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/001037\/WC500069763.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB9|cit9","unstructured":"\u00ae http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000363\/WC500042310.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB10|cit10","unstructured":"\u00ae http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/RoActemra\/emea-combined-h955es.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB11|cit11","unstructured":"http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/Mabthera\/emea-combined-h165es.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB12|cit12","unstructured":"http:\/\/www.ema.europa.eu\/humandocs\/PDFs\/EPAR\/orencia\/emea-combined-h701es.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis and Rheumotism"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis and Rheumotism"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor Receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/art.11142","article-title":"Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis","volume":"48","author":"Kremer","year":"2003","journal-title":"Arthritis and Rheumotism"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor_monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial (ATTRACT)","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthrtitis refractory to anti-tumour necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis and Rheumotism"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis and Rheumotism"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effect of abatacept in patients with methotrexate resistant active rheumatoid arthritis; randomised trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Annals of the Internal Medicine"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial: RADIATE","volume":"67","author":"Emery","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor \u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study","volume":"68","author":"Keystone","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis and Rheumotism"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar2859","article-title":"Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1\u2003year: results from the RAPID 1 randomized controlled trial","volume":"11","author":"Strand","year":"2009","journal-title":"Arthritis Research & Therapy"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4\u2003weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.24828","article-title":"Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis","volume":"61","author":"Kavanaugh","year":"2009","journal-title":"Arthritis and Rheumotism"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","article-title":"Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial","volume":"41","author":"Choy","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB32|cit32","unstructured":"Wells GA Sultan SA Chen L Khan M Coyle D 2009 Indirect evidence: indirect treatment comparisons in meta-analysis http:\/\/www.cadth.ca\/media\/pdf\/H0462_itc_tr_e.pdf"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1157\/13113299","article-title":"Equivalencia Terap\u00e9utica: concepto y niveles de evidencia","volume":"129","author":"Delgado","year":"2007","journal-title":"Medicina Cl\u00ednica (Barcelona)"},{"key":"10.1111\/j.1365-2710.2011.01292.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0025-7753(02)72393-2","article-title":"El intervalo de confianza: algo m\u00e1s que un valor de significaci\u00f3n estad\u00edstica","volume":"118","author":"Argim\u00f3n","year":"2002","journal-title":"Medicina Cl\u00ednica (Barcelona)"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2011.01292.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2011.01292.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:17Z","timestamp":1671818657000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2011.01292.x"}},"subtitle":["Biological Treatments in Rheumatoid Arthritis"],"short-title":[],"issued":{"date-parts":[[2011,8,10]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01292.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,10]]}}}